Literature DB >> 6308059

Metabolic compensation for profound erythrocyte adenylate kinase deficiency. A hereditary enzyme defect without hemolytic anemia.

E Beutler, D Carson, H Dannawi, L Forman, W Kuhl, C West, B Westwood.   

Abstract

A child with hemolytic anemia was found to have severe erythrocyte adenylate kinase (AK) deficiency, but an equally enzyme-deficient sibling had no evidence of hemolysis. No residual enzyme activity was found in erythrocytes by spectrophotometric methods that could easily have detected 0.1% of normal activity. However, concentrated hemolysates were shown to have the capacity to generate small amounts of ATP and AMP from ADP after prolonged incubation. Hemolysates could also catalyze the transfer of labeled gamma-phosphate from ATP to ADP. Intact erythrocytes were able to transfer phosphate from the gamma-position of ATP to the beta-position, albeit at a rate substantially slower than normal. They could also incorporate 14C-labeled adenine into ADP and ATP. Thus, a small amount of residual AK-like activity representing about 1/2,000 of the activity normally present could be documented in the deficient erythrocytes. The residual activity was not inhibited by N-ethylmaleimide, which completely abolishes the activity of the normal AK1 isozyme of erythrocytes. The minute amount of residual activity in erythrocytes could represent a small amount of the AK2 isozyme, which has not been thought to be present in erythrocytes, or the activity of erythrocyte guanylate kinase with AMP substituting as substrate for GMP. Peripheral blood leukocytes, cultured skin fibroblasts, and transformed lymphoblasts from the deficient subject manifested about 17, 24, and 74%, respectively, of the activity of the concurrent controls. This residual activity is consistent with the existence of genetically independent AK isozyme, AK2, which is known to exist in these tissues. The cause of hemolysis in the proband was not identified. Possibilities include an unrelated enzyme deficiency or other erythrocyte enzyme defect and intraction of another unidentified defect with AK deficiency.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6308059      PMCID: PMC1129224          DOI: 10.1172/JCI111014

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  16 in total

1.  The removal of leukocytes and platelets from whole blood.

Authors:  E Beutler; C West; K G Blume
Journal:  J Lab Clin Med       Date:  1976-08

2.  Adenylate kinases in man: evidence for a third locus.

Authors:  D E Wilson; S Povey; H Harris
Journal:  Ann Hum Genet       Date:  1976-01       Impact factor: 1.670

3.  [Acquired erythroenzymopathies. II. Adenylate kinase deficiency in hemopathies].

Authors:  P Boivin; C Galand; M C Demartial
Journal:  Pathol Biol (Paris)       Date:  1972-10

4.  Adenylate kinase in human tissue. I. Organ specificity of adenylate kinase isoenzymes.

Authors:  P J Russell; J M Horenstein; L Goins; D Jones; M Laver
Journal:  J Biol Chem       Date:  1974-03-25       Impact factor: 5.157

5.  Erythrocyte adenylate-kinase deficiency.

Authors:  A Szeinberg; S Gavendo; D Cahane
Journal:  Lancet       Date:  1969-02-08       Impact factor: 79.321

6.  Isoenzymes of adenylate kinase in human tissue.

Authors:  J C Khoo; P J Russell
Journal:  Biochim Biophys Acta       Date:  1972-04-07

7.  Adenosine triphosphate-guanosine 5'-phosphate phosphotransferase. IV. Isozymes in human erythrocytes and Sarcoma 180 ascites cells.

Authors:  K C Agarwal; R E Parks
Journal:  Mol Pharmacol       Date:  1972-03       Impact factor: 4.436

8.  Phosphorus compounds in the human erythrocyte.

Authors:  G R Bartlett
Journal:  Biochim Biophys Acta       Date:  1968-03-11

9.  [Congenital deficiency erythrocyte adenylate-kinase].

Authors:  P Boivin; C Galand; J Hakim; D Simony; M Seligman
Journal:  Presse Med       Date:  1970-06       Impact factor: 1.228

10.  [A new erythroenzymopathy: congenital non-spherocytic hemolytic anemia and hereditary erythrocytic adenylate kinase deficiency].

Authors:  P Boivin; C Galand; J Hakim; D Simony; M Seligman
Journal:  Presse Med       Date:  1971-01-30       Impact factor: 1.228

View more
  4 in total

Review 1.  Purine import into malaria parasites as a target for antimalarial drug development.

Authors:  I J Frame; Roman Deniskin; Avish Arora; Myles H Akabas
Journal:  Ann N Y Acad Sci       Date:  2014-11-25       Impact factor: 5.691

2.  Erythrocytic adenosine monophosphate as an alternative purine source in Plasmodium falciparum.

Authors:  María B Cassera; Keith Z Hazleton; Paul M Riegelhaupt; Emilio F Merino; Minkui Luo; Myles H Akabas; Vern L Schramm
Journal:  J Biol Chem       Date:  2008-09-17       Impact factor: 5.157

3.  Whole exome sequencing of a consanguineous family identifies the possible modifying effect of a globally rare AK5 allelic variant in celiac disease development among Saudi patients.

Authors:  Jumana Yousuf Al-Aama; Noor Ahmad Shaik; Babajan Banaganapalli; Mohammed A Salama; Omran Rashidi; Ahmed N Sahly; Mohammed O Mohsen; Harbi A Shawoosh; Hebah Ahmad Shalabi; Mohammad Al Edreesi; Sameer E Alharthi; Jun Wang; Ramu Elango; Omar I Saadah
Journal:  PLoS One       Date:  2017-05-15       Impact factor: 3.240

4.  Red cell adenylate kinase deficiency in China: molecular study of 2 new mutations (413G > A, 223dupA).

Authors:  Sijia He; Hongbo Chen; Xia Guo; Ju Gao
Journal:  BMC Med Genomics       Date:  2022-05-04       Impact factor: 3.622

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.